Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328731 | Critical Reviews in Oncology/Hematology | 2015 | 13 Pages |
Abstract
There is increasing evidence for the use of circulating tumor cells (CTCs) as a “liquid biopsy” for early detection of lung cancer recurrence, prognosticating disease and monitoring treatment response. Further, CTC molecular analysis and interrogation of single cells hold significant potential in providing insights into tumor biology and the metastatic process. Ongoing research will likely see the translation of CTCs as a prognostic and predictive biomarker in both small cell, and non-small cell, lung cancer to routine clinical practice.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Annette Tognela, Kevin J. Spring, Therese Becker, Nicole J. Caixeiro, Victoria J. Bray, Po Yee Yip, Wei Chua, Stephanie H. Lim, Paul de Souza,